The fusion of the androgen‐related transmembrane protease serine 2 gene with the ETS‐related gene (TMPRSS2‐ERG), which accounts for 90% of prostate cancer fusions, has been linked to aggressive tumors with a fatal phenotype and a poor prognosis.129, 130. The gene discussed is ERG; the disease is prostate cancer.